Jürgen Debus is Professor of Radiotherapy at the University of Heidelberg and Director of the Department of Radiation Oncology, Heidelberg.
His fields of Interest are Precision Radiotherapy, Ion beam radiotherapy, radiation biology, radiation oncology.
Since 1997 he is chair of the German Heavy Ion Radiotherapy Project.
Awards: Hermann Holthusen; Erwin Schrödinger; First Innovation Award of the medical science association (AWMF,VUD); Alfred-Breit Award of the German Society for Radiation Oncology
Catherine completed her engineering studies before going on medical physicist training in Paris, France, in 1999. In 2003, she completed her PhD on regularization methods applied to IMRT and dose distribution qualitative evaluation. Catherine worked as a medical physicist and participated in the commissioning of one of the first TomoTherapy units installed in France in 2006. She has worked over 15 years in IMRT from beginning with Siemens Linacs, then Varian and on IG-IMRT with TomoTherapy. She is now working at Centre Antoine Lacassagne in Nice; the platform offers two TomoTherapy units, a CK, two Varian, protons low energy and protons high energy in june 2016. Catherine has published on TomoTherapy treatment evaluation and brachytherapy. She is very invested in quality control of clinical trials and clinical development.
1: Troussier I, Huguet F, Servagi-Vernat S, Benahim C, Khalifa J, Darmon I, Ortholan C, Krebs L, Dejean C, Fenoglietto P, Vieillot S, Bensadoun RJ, Thariat J. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy]. Cancer Radiother. 2015 Apr;19(2):127-38
2 : Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, Malicki J, Bogusz M, Gasparotto C, Grau C; HERO Consortium, Kokobobo A, Sedlmayer F, Slobina E, Coucke P, Gabrovski R, Vosmik M, Eriksen JG, Jaal J, Dejean C, Polgar C, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014 Aug;112(2):178-86
3: Thariat J, Fric D, Kerr C, Leysalle A, Angellier G, Dejean C, Tuillier T, Bensadoun RJ, Lagrange JL. [Advances in radiation oncology for metastatic bone disease]. Bull Cancer. 2013 Nov;100(11):1187-97
4: Sargos P, Dejean C, de Figueiredo BH, Brouste V, Nguyen Bui B, Italiano A, Stoeckle E, Kantor G. High-dose pre-operative helical TomoTherapy (54 Gy) for retroperitoneal liposarcoma. Radiat Oncol. 2012 Dec 17;7:214.
5: Veresezan P, Dejean C, Gautier M, Thariat J. Adaptive radiotherapy for H&N cancers : what forms of rescheduling? Debate surrounding a clinical case. Journal of Radiotherapy and Medical Oncology. 2012 vol XVII; 78-83.
6 : Giraud P, Kantor G, Yassa M, Zefkili S, Dejean C, Lisbona A, Campana F, Mahé MA. Two-year clinical experience with TomoTherapy: the French national cancer institute project on implementing new technology. Cancer Invest. 2011;29(8):557-63.
7 : Haddad H, Dejean C, Henriques de Figueiredo B, Sargos P, Caron J, Stoeckle E, Bui BN, Italiano A, Gille O, Kantor G. Helical TomoTherapy for axial and paraspinal tumours: experience of Institut Bergonié (14 cases). Cancer Radiother. 2011 Aug;15(5):404-12.
8 :Gaundong Mbéthé G-, Dejean C, Henriques de Figueiredo B, Sargos P, Italiano A, Kantor G. Multifocal langerhans cell histiocytosis of bone: Indications for radiotherapy. Cancer/Radiotherapie. 2010;14(8):759-62.
9 : Dejean C, Kantor G, Henriques De Figueiredo B, Lisbona A, Mahé M-, Mervoyer A, et al. Helical TomoTherapy: Description and clinical applications. Bull Cancer. 2010;97(7):783-9.
Dr Alain Fourquet is currently Chairman of the Department of Radiation Oncology at the Institut Curie in Paris. He has published over 230 articles in peer-reviewed journals, in addition to book chapters, reviews and abstracts. The department operates 12 treatment machines, including linacs, helicoïdal tomotherapies, stereotactic whole-body irradiation, and proton therapy.
His research interests focus on clinical breast cancer, including technical improvements in the delivery of breast irradiation, ductal carcinoma in situ, the study of long-term outcome after treatment and its consequences on follow-up modalities. He is involved in translational research projects on breast cancer in young women, and the ways to improve radiation sensitivity with concurrent chemotherapy and targeted treatments.
Dr Fourquet is a member of ESTRO, ASTRO, the Société Française de Sénologie et de Pathologie Mammaire, and the EORTC Breast and Radiotherapy Groups. He served as Chairman of the 7th European Breast Cancer Conference (EBCC-7)
Professor Cai Grau was born in 1958 in Denmark. He is professor in radiation oncology at the Institute of Clinical Medicine at Aarhus University and heading the interdisciplinary radiotherapy research at the Department of Oncology, Aarhus University Hospital in Aarhus, Denmark. He is also director of the Danish national Center for Interventional Research in Radiation Oncology (CIRRO).
Professor Grau received his MD in 1987 and defended his DMSc in 1994 at Aarhus University. After clinical training in Aarhus and Vancouver he became board certified specialist in oncology (radiation oncology and medical oncology) in 1998. His main area of interest is research in head and neck oncology, high precision radiotherapy and proton therapy.
Professor Grau is active in several national and international research collaborative groups, including the Danish Head and Neck Cancer Group (DAHANCA), EORTC, IAEA, and is currently chairing the European Society for Radiotherapy and Oncology (ESTRO) task force on Health Economics in Radiation Oncology (HERO).
Professor Grau has served as the president of the Danish Society for Clinical Oncology, the Danish Society for Head and Neck Oncology and Scandinavian Society for Head and Neck Oncology. He was secretary and member of the board of ESTRO from 2007-2011 and member of Danish Medical Research Council 2008-2013. He is currently member of the board of European Head and Neck Society, the Scientific Committee of the Danish Cancer Society, the Scientific Audit Committee of EORTC, and the Scientific Advisory Board of the Helmholz Zentrum Dresden-Rössendorf (HZDR).
He has been the supervisor of 14 completed and 5 ongoing Ph.D. and DMSc. studies within radiotherapy, medical physics and head and neck oncology. He has published more than 170 scientific publications.
Geoff completed a BSc in Physics at the University of Durham, UK, before commencing training as a Medical Physicist in Birmingham in 1999. In 2004 he completed his PhD at the University of Birmingham, UK studying the health effects of low doses of ionising radiation –specifically examining the biological effectiveness of low LET radiation, and studying the impact of this work on the UK breast screening programme. After his PhD, Geoff was appointed as a medical physicist at the Queen Elizabeth hospital in Birmingham. He has over 10 years experience in stereotactic radiosurgery, first working with a BrainLab headframe and a modified conventional linear accelerator and with a CyberKnife unit since 2013. Since 2013 Geoff has been the lead physicist and Medical Physics Expert for stereotactic radiosurgery at the Queen Elizabeth hospital, treating about 200 patients per year with the CyberKnife system. Geoff has published on small field dosimetry, the use of Cerenkov imaging from the CyberKnife system as well as clinical results from the 15 year programme of stereotactic radiosurgery in Birmingham. He is an honorary research fellow for the School of Physics and Astronomy at the University of Birmingham, and lecturer for an MSc course in Clinical Oncology.
Real-time Cherenkov emission portal imaging during CyberKnife radiotherapy. (2015) Physics in Medicine and Biology (60) N419-N425. Yiannis Roussakis, Rongxiao Zhang, Geoff Heyes, Gareth Webster, Suzannah Mason, Stuart Green, Brian Pogue, Hamid Dehghani
Linear Accelerator Stereotactic Radiosurgery for Vestibular Schwannomas: A UK Series (2014) Clinical Oncology (6) 309-315. H Benghiat, G Heyes, P Nightingale, A Hartley, M Tiffany, D Spooner, JI Geh, G Cruickshank, RM Irving, P Sanghera
Evaluation of a synthetic single-crystal diamond detector for relative dosimetry measurements on a CyberKnife (2014). The British journal of radiology (87) 87(1035), 20130768. A Chalkley, G Heyes
Mammography-oncogenecity at low doses (2009) Journal Of Radiological Protection. 29(2A): A123-A132. Heyes, G. J., A. J. Mill, et al.
Small field measurements with a novel silicon position sensitive diode array (2009) Physics in Medicine and Biology. 54 (2009) 485–495. S. Manolopoulos, C. Wojnecki, R. Hugtenburg, M. A. Jaafar Sidek, G. Heyes, and S. Green
Enhanced biological effectiveness of low energy x-rays and implications for the UK breast screening programme (2006) British Journal of Radiology 79 2006 195-200. G.J Heyes, A. J Mill and M. W Charles.
The neoplastic transformation potential of mammography x-rays and Atomic Bomb spectrum radiation (2004). Radiation Research, 162(2) 120-127. G.J.Heyes and A.J.Mill
Dr Vincent Khoo is Head of Department of Clinical Oncology, Royal Marsden Hospital (RMH) and Lead Clinical Oncologist, Urology Oncology Unit, Chelsea Branch; Honorary Consultant Clinical Oncologist, St George's Hospital; Honorary Senior Lecturer and Faculty, Institute of Cancer Research, University of London and Honorary Associate Professor, Austin Health and University of Melbourne, Australia. He has trained and worked in clinical oncology in UK, USA and Australia. His Unit specialises in urological cancers and provides a comprehensive array of therapies from stereotactic and intensity modulated radiotherapy to brachytherapy and systemic therapies from hormonal treatments to chemotherapy as well as targeted agents.
He is a member of several national and international committees including His committee membership includes UK National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Group, National Radiotherapy Implementation Group, NCRI Prostate Cancer Clinical Studies Group, NCRI Penile Cancer Clinical Studies Group, Clinical Trials Awards and Advisory Committee (CTACC) Cancer Research UK., UK Familial Prostate Cancer, Clinical Oncology Editorial Board, ESTRO and ECCO scientific sub-committees.
He is advisory and reviewer for several cancer funds and international journals. He has active research interests in multimodality imaging, combined modality therapy including targeted agents, as well as image guided and adaptive radiotherapy. He has published over 180 papers and chapters.
Raphaël Moeckli completed his MSc degree in Ecole Polytechnique Fédérale de Lausanne. He completed his PhD in medical imaging at the University of Lausanne in 2001. He is certified Swiss medical physicists since 1999, head of the radiation therapy group in Institute of Radiation Physics and head physicist in the Radio-Oncology Department in CHUV Lausanne since 2001.
He is Maître d’Enseignement et de Recherche since 2005 and Privat Docent since 2007, both in Lausanne University. His main fields of research are TomoTherapy, multicriteria optimisation and 4D treatments. He is and has been director and experts for various national and international PhD thesis juries.
He is past president of the Swiss Society of Radiobiology and Medical Physics and he has been active in different working groups having issued Swiss recommendations about good practice in radiation therapy. He was member of different scientific committees of ESTRO meetings as well as other Swiss and international meetings.
Jean-Philippe PIGNOL is an MD specialist in Radiation Oncologist with a PhD in Nuclear Physics. In 2008 he became a Full Professor at the University of Toronto, in the Departments of Radiation Oncology, Medical Biophysics and at the Institute of Medical Sciences. Since August 2014 he is Professor and Chair in the department of Radiation Oncology, Erasmus Medical Center in Rotterdam, with a cross appointment as Professor at TU Delft in The Netherlands. His research has been supported by more than $14M in fundings over 14 years, and focuses on the clinical evaluation of novel radiation techniques. He has published over 100 articles in international journals.